One story, two headlines, Tech
Ozempic, Wegovy and other GLP-1 drugs to carry vision loss warning after FDA finds rare eye risk
6 newsrooms covered this story. These two put it most differently.
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Every headline, by side
Left 2
- FDA orders blindness risk warning on weight loss drugs
Sky News, lean left
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
CNBC, lean left
Right 1
- FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Fox Business, lean right
Centre 1
Hindustan TimesNot rated 2
Gizmodo
Ars TechnicaThe pair is the two headlines on this story that share the fewest words. Highlighted: words that judge or colour what happened (verdicts, conflict, emotion, hedging), from a fixed list, that the other headline doesn’t use. Lean ratings are AllSides’s.
Every side, every morning
Today by email: the five stories worth knowing, with how each side is covering them. Free.